Drug
Npi 001
Npi 001: highest development phase Phase 3, developed by Nacuity Pharmaceuticals, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Nacuity Pharmaceuticals, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| NPI-001 NCT07710196 | Phase 3 | Retinitis Pigmentosa (RP) |
Latest
No recent events.
Follow Npi 001 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.